Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behçet's disease

Arthritis Research and Therapy

Volumn 14, Issue 3, 2012, Pages

  Sugita, Sunao ^a,b   Kawazoe, Yuko ^a   Imai, Ayano ^a   Yamada, Yukiko ^a   Horie, Shintaro ^a   Mochizuki, Manabu ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b RIKEN Center for Biosystems Dynamics Research   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIBODY; GAMMA INTERFERON; GAMMA INTERFERON ANTIBODY; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 4 ANTIBODY; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ANIMAL CELL; ARTICLE; AUTOIMMUNE UVEITIS; BEHCET DISEASE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOCYTE DIFFERENTIATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TH17 CELL; ANIMAL; CELL DIFFERENTIATION; COCULTURE; CYTOLOGY; DRUG EFFECT; IMMUNOLOGY; UVEITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BEHCET SYNDROME; CELL DIFFERENTIATION; COCULTURE TECHNIQUES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; MICE; TH17 CELLS; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 84860290306     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3824     Document Type: Article

References (42)

1. Takeuchi M, Hokama H, Tsukahara R, Kezuka T, Goto H, Sakai J, Usui M. Risk and prognostic factors of poor visual outcome in Behcet's disease with ocular involvement. Graefes Arch Clin Exp Ophthalmol 2005, 243:1147-1152. 10.1007/s00417-005-0005-8, 15983811.
2. Raziuddin S, al-Dalaan A, Bahabri S, Siraj AK, al-Sedairy S. Divergent cytokine production profile in Behçet's disease. Altered Th1/Th2 cell cytokine pattern. J Rheumatol 1998, 25:329-333.
3. Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K. Cytokine profile in Behcet's disease patients. Relationship with disease activity. Scand J Rheumatol 2002, 31:205-210. 10.1080/030097402320318387, 12369651.
4. Hamzaoui K, Bouali E, Ghorbel I, Khanfir M, Houman H, Hamzaoui A. Expression of Th-17 and RORγt mRNA in Behçet's Disease. Med Sci Monit 2011, 17:227-234.
5. Takeuchi M, Usui Y, Okunuki Y, Zhang L, Ma J, Yamakawa N, Hattori T, Kezuka T, Sakai J, Goto H. Immune responses to interphotoreceptor retinoid-binding protein and S-antigen in Behcet's patients with uveitis. Invest Ophthalmol Vis Sci 2010, 51:3067-3075. 10.1167/iovs.09-4313, 20089879.
6. Chi W, Zhu X, Yang P, Liu X, Lin X, Zhou H, Huang X, Kijlstra A. Upregulated IL-23 and IL-17 in Behçet patients with active uveitis. Invest Ophthalmol Vis Sci 2008, 49:3058-3064. 10.1167/iovs.07-1390, 18579762.
7. Mizuki N, Meguro A, Ota M, Ohno S, Shiota T, Kawagoe T, Ito N, Kera J, Okada E, Yatsu K, Song YW, Lee EB, Kitaichi N, Namba K, Horie Y, Takeno M, Sugita S, Mochizuki M, Bahram S, Ishigatsubo Y, Inoko H. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet's disease susceptibility loci. Nat Genet 2010, 42:703-706. 10.1038/ng.624, 20622879.
8. Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, Satorius C, Le JM, Yang B, Korman BD, Cakiris A, Aglar O, Emrence Z, Azakli H, Ustek D, Tugal-Tutkun I, Akman-Demir G, Chen W, Amos CI, Dizon MB, Kose AA, Azizlerli G, Erer B, Brand OJ, Kaklamani VG, Kaklamanis P, Ben-Chetrit E, Stanford M, Fortune F, Ghabra M, Ollier WE, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. Nat Genet 2010, 42:698-702. 10.1038/ng.625, 2923807, 20622878.
9. Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, Sugita S, Ueno S, Yoshizaki K, Inaba G. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 2004, 31:1362-1368.
10. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet 2001, 358:295-296. 10.1016/S0140-6736(01)05497-6, 11498218.
11. Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J, Schlincker A, Martín-Mola E. Effect of infliximab on threatening panuveitis in Behcet's disease. Lancet 2001, 358:1644.
12. Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, Gül A. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease: an open-label trial. Arthritis Rheum 2005, 52:2478-2484. 10.1002/art.21231, 16052571.
13. Tabbara KF, Al-Hemidan AI. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behcet disease. Am J Ophthalmol 2008, 146:845-850. 10.1016/j.ajo.2008.09.010, 18929351.
14. Yamada Y, Sugita S, Tanaka H, Kamoi K, Kawaguchi T, Mochizuki M. Comparison of infliximab versus cyclosporine during the initial 6-month treatment period in Behcet's disease. Br J Ophthalmol 2010, 94:284-288. 10.1136/bjo.2009.158840, 19692382.
15. Yamada Y, Sugita S, Tanaka H, Kamoi K, Takase H, Mochizuki M. Timing of recurrent uveitis in patients with Behcet's disease receiving infliximab treatment. Br J Ophthalmol 2011, 95:205-208. 10.1136/bjo.2009.168856, 20542984.
16. Sugita S, Yamada Y, Mochizuki M. Relationship between serum infliximab levels and acute uveitis attacks in patients with Behçet's disease. Br J Ophthalmol 2011, 95:549-552. 10.1136/bjo.2009.174888, 20584716.
17. Sugita S, Yamada Y, Kaneko S, Horie S, Mochizuki M. Induction of regulatory T cells by infliximab in Behçet's disease. Invest Ophthalmol Vis Sci 2011, 52:476-484. 10.1167/iovs.10-5916, 20861484.
18. Behcet's Disease Research Committee of Japan Behcet's disease: guide to diagnosis of Behcet's disease. Jpn J Ophthalmol 1974, 18:291-294. Behcet's Disease Research Committee of Japan.
19. Sugita S, Usui Y, Horie S, Futagami Y, Aburatani H, Okazaki T, Honjo T, Takeuchi M, Mochizuki M. T-cell suppression by programmed cell death 1 ligand 1 on retinal pigment epithelium during inflammatory conditions. Invest Ophthalmol Vis Sci 2009, 50:2862-2870. 10.1167/iovs.08-2846, 19182257.
20. Caspi RR, Roberge FG, Chan CC, Wiggert B, Chader GJ, Rozenszajn LA, Lando Z, Nussenblatt RB. A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens. J Immunol 1988, 140:1490-1495.
21. Thurau SR, Chan CC, Nussenblatt RB, Caspi RR. Oral tolerance in a murine model of relapsing experimental autoimmune uveoretinitis (EAU): induction of protective tolerance in primed animals. Clin Exp Immunol 1997, 109:370-376. 10.1046/j.1365-2249.1997.4571356.x, 1904752, 9276535.
22. Avichezer D, Silver PB, Chan CC, Wiggert B, Caspi RR. Identification of a new epitope of human IRBP that induces autoimmune uveoretinitis in mice of the H-2b haplotype. Invest Ophthalmol Vis Sci 2000, 41:127-131.
23. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238. 10.1038/nature04753, 16648838.
24. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006, 24:179-189. 10.1016/j.immuni.2006.01.001, 16473830.
25. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol 2009, 27:485-517. 10.1146/annurev.immunol.021908.132710, 19132915.
26. Amadi-Obi A, Yu CR, Liu X, Mahdi RM, Clarke GL, Nussenblatt RB, Gery I, Lee YS, Egwuagu CE. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 2007, 13:711-718. 10.1038/nm1585, 17496900.
27. Chi W, Yang P, Li B, Wu C, Jin H, Zhu X, Chen L, Zhou H, Huang X, Kijlstra A. IL-23 promotes CD4+ T cells to produce IL-17 in Vogt-Koyanagi-Harada disease. J Allergy Clin Immuno 2007, 119:1218-1224.
28. Yoshimura T, Sonoda KH, Miyazaki Y, Iwakura Y, Ishibashi T, Yoshimura A, Yoshida H. Differential roles for IFN-gamma and IL-17 in experimental autoimmune uveoretinitis. Int Immunol 2008, 20:209-214.
29. Yoshimura T, Sonoda KH, Ohguro N, Ohsugi Y, Ishibashi T, Cua DJ, Kobayashi T, Yoshida H, Yoshimura A. Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology (Oxford) 2009, 48:347-354.
30. Cui Y, Shao H, Lan C, Nian H, O'Brien RL, Born WK, Kaplan HJ, Sun D. Major role of gamma delta T cells in the generation of IL-17+ uveitogenic T cells. J Immunol 2009, 183:560-567. 10.4049/jimmunol.0900241, 19542467.
31. Medvedev A, Chistokhina A, Hirose T, Jetten AM. Genomic structure and chromosomal mapping of the nuclear orphan receptor ROR gamma (RORC) gene. Genomics 1997, 46:93-102. 10.1006/geno.1997.4980, 9403063.
32. He YW, Deftos ML, Ojala EW, Bevan MJ. RORgamma t, a novel isoform of an orphan receptor, negatively regulates Fas ligand expression and IL-2 production in T cells. Immunity 1998, 9:797-806. 10.1016/S1074-7613(00)80645-7, 2776668, 9881970.
33. Sartani G, Silver PB, Rizzo LV, Chan CC, Wiggert B, Mastorakos G, Caspi RR. Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming. Invest Ophthalmol Vis Sci 1996, 37:2211-2218.
34. Ziegler SF, Buckner JH. FOXP3 and the regulation of Treg/Th17 differentiation. Microbes Infect 2009, 11:594-598. 10.1016/j.micinf.2009.04.002, 2728495, 19371792.
35. Valencia X, Stephens G, Goldbach-Mansky R, Wilson M, Shevach EM, Lipsky PE. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 2006, 108:253-261. 10.1182/blood-2005-11-4567, 1895836, 16537805.
36. Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med 2007, 204:33-39. 10.1084/jem.20061531, 2118431, 17200409.
37. Hamzaoui K. Th17 cells in Behçet's disease: a new immunoregulatory axis. Clin Exp Rheumatol 2011, 29:71-76.
38. Hamzaoui K, Borhani Haghighi A, Ghorbel IB, Houman H. RORC and Foxp3 axis in cerebrospinal fluid of patients with neuro-Behçet's disease. J Neuroimmunol 2011, 233:249-453. 10.1016/j.jneuroim.2011.01.012, 21367463.
39. Nakamura S, Sugita M, Tanaka T, Tanaka S, Isoda F, Ohno S. In vitro tumor necrosis factor-alpha producibility in peripheral monocytes in patients with Behcet's disease. Nippon Ganka Gakkai Zasshi 1992, 96:1282-1285.
40. Sakaguchi M, Sugita S, Sagawa K, Itoh K, Mochizuki M. Cytokine production by T cells infiltrating in the eye of uveitis patients. Jpn J Ophthalmol 1998, 42:262-268. 10.1016/S0021-5155(98)00016-1, 9749865.
41. Sugita S, Takase H, Taguchi C, Mochizuki M. The role of soluble TNF receptors for TNF-α in uveitis. Invest Ophthalmol Vis Sci 2007, 48:3246-3252. 10.1167/iovs.06-1444, 17591895.
42. Zhang R, Qian J, Guo J, Yuan YF, Xue K. Suppression of experimental autoimmune uveoretinitis by anti-IL-17 antibody. Curr Eye Res 2009, 34:297-303. 10.1080/02713680902741696, 19373578.